Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage

Fig. 3

Treatment time-line for ICI and anti-tuberculosis in patients with tumor and active tuberculosis. TB tuberculosis, ICI immune checkpoint inhibitor, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, ESCC esophageal squamous cell carcinoma, CSCC cutaneous squamous cell carcinoma, HNSCC head and neck squamous cell carcinoma, HCC hepatocellular carcinoma, BC breast cancer, PR partial response, PD progression disease

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us